The weight-loss drug divide: private prescribing is lowest where need is greatest

Caroline Ruda/Shutterstock For many people living with obesity, Wegovy and Mounjaro offer the possibility of substantial weight loss without surgery. Yet data from one private provider points to a troubling divide: prescription rates of these drugs in England are lowest in communities where obesity is most common. Wegovy contains semaglutide, which acts on the GLP-1 […]

Continue Reading